Latest / JACC Specialty Journals
Oncologic Benefits and Cardiovascular Risks of Pembrolizumab: Insights From a Nationwide Lung Adenocarcinoma Cohort | JACC: Asia
Commentary by Dr. Koohyar Ahmadzadeh.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.